PDS Biotechnology Corporation (PDSB)
Summary
PDSB Chart
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
PDS Biotechnology Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 173,605 | $133,641.15 | $125,516.41 | -$8,124.74 | -6.08% |
 Adam K. Wright Kathleen S. Wright Associates Inc. | 7,000 | $27,720 | $5,233.9 | -$22,486.1 | -81.12% |
 Cornelius T. McDonald III Wealth Group, Ltd. | 13,399 | $21,840.37 | $9,664.7 | -$12,175.67 | -55.75% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 14,800 | $34,584 | $10,690.04 | -$23,893.96 | -69.09% |
 Carmen McClennon WR Wealth Planners, LLC | 2,000 | $7,920 | $1,434.8 | -$6,485.2 | -81.88% |
PDS Biotechnology Corporation (PDSB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PDS Biotechnology Corporation ever had a stock split?
PDS Biotechnology Corporation Profile
| Biotechnology Industry | Healthcare Sector | Frank K. Bedu-Addo CEO | NASDAQ (CM) Exchange | 70465T107 CUSIP |
| US Country | 21 Employees | - Last Dividend | 18 Mar 2019 Last Split | 1 Oct 2015 IPO Date |
Overview
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company engaged in the development of innovative cancer immunotherapies. Based in Princeton, New Jersey, and founded in 2005, PDS Biotech specializes in advancing treatment options for various types of cancer through its proprietary immunotherapy platforms. The company's strategic collaborations with notable institutions, including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH, underscore its commitment to pioneering the next generation of cancer treatments.
Products and Services
- PDS0101 (HPV16)
This leading product candidate is currently in Phase II clinical trials and offers a novel approach as a first-line treatment for recurrent/metastatic head and neck cancer and other malignancies associated with the human papillomavirus (HPV). PDS0101 leverages the immune system to target and eradicate cancer cells, signifying a significant advancement in treating HPV-driven cancers.
- PDS0102
An investigational immunotherapy utilizing the T cell receptor gamma alternate reading frame protein (TARP) for the treatment of prostate and breast cancers. PDS0102 is designed to activate the body’s immune response against tumor-associated antigens, offering a potentially powerful weapon against these prevalent cancers. Currently in preclinical trials, it represents a novel approach to immunotherapy.
- PDS0103
Targeting ovarian, colorectal, lung, and breast cancers, PDS0103 is in the preclinical trial phase. It employs innovative technology to stimulate the immune system, aiming to offer a new therapeutic option for treating a range of complex cancers. The unique mechanism of action holds promise for improving outcomes in some of the most challenging to treat cancers.
- PDS01ADC
A groundbreaking Interleukin 12 fused antibody-drug conjugate, PDS01ADC, enhances T cell proliferation, potency, and longevity within the tumor microenvironment. This investigational therapy is under development to transform cancer treatment by creating a more hostile environment for tumors through an enhanced immune response.
- PDS0104
A Tyrosinase-related Protein 2 targeted immunotherapy, PDS0104 is designed to trigger a potent T cell attack against melanoma. As a novel investigational candidate, it represents a strategic shift towards targeted immunotherapies in melanoma treatment, focusing on stimulating the immune system to recognize and fight cancer cells.
- PDS0202
This innovative investigational influenza vaccine is positioned to generate broad and robust antibody and T cell responses, offering protection against continually evolving strains of seasonal flu and potential pandemic threats. PDS0202 exemplifies the company’s expansion into vaccine development, leveraging its immunotherapy expertise to address viral diseases.
